Vasopressin and desmopressin in central diabetes insipidus: Adverse effects and clinical considerations

Roy J. Kim, Clara Malattia, Michaela Allen, Thomas Moshang, Mohamad Maghnie

Research output: Contribution to journalArticle


The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerabitity make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalPediatric Endocrinology Reviews
Issue numberSUPPL. 1
Publication statusPublished - Nov 2004



  • Adverse effects
  • Children
  • Desmopressin
  • Diabetes insipidus
  • Vasopressin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this